Two-Drug attack aims to outsmart liver Cancer's stronghold
NCT ID NCT04862949
Summary
This study tested if combining two drugs (atezolizumab and bevacizumab) could better control advanced liver cancer, especially tumors inside the liver itself. It involved 131 patients with advanced liver cancer who received this combination as their first treatment. Researchers specifically measured how tumors in the liver responded compared to tumors that had spread to other organs.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cha Medical Center
Seongnam-si, Gyeonggi-do, 13496, South Korea
Conditions
Explore the condition pages connected to this study.